A 1 to 1000 SARS-CoV-2 reinfection proportion in members of a large healthcare provider in Israel: a preliminary report
Perez, G.; Banon, T.; Gazit, S.; Ben Moshe, S.; Wortsman, J.; Grupel, D.; Peretz, A.; Ben Tov, A.; Chodick, G.; Mizrahi- Reuveni, M.; Patalon, T.
Show abstract
With more than 100 million confirmed COVID-19 cases as of March 2021, reinfection is still considered to be rare. In light of increasing reports of reinfected COVID-19 patients, the need to better understand the real risk for reinfection is critical, with potential effects on public health policies aimed at containing the spread of SARS-CoV-2. In this descriptive preliminary report, we conducted a large-scale assessment on the country level of the possible occurrence of COVID-19 reinfection within the members of a large healthcare provider in Israel. Out of 149,735 individuals with a documented positive PCR test between March 2020 and January 2021, 154 had two positive PCR tests at least 100 days apart, reflecting a reinfection proportion of 1 per 1000. Given our strict inclusion criteria, we believe these numbers represent true reinfection incidence in MHS and should be clinically regarded as such.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Impact of vaccination and risk factors on COVID-19 mortality amid delta wave in Libya: a single centre cohort study 95%
- First and second waves of coronavirus disease-19: A comparative study in hospitalized patients in Reus, Spain 95%
- Assessing the impact of the Gamma variant on COVID-19 Patient admissions in a Southern Brazilian tertiary hospital - A comparison of dual pandemic phases 95%
Similar papers in this journal
- Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected with Omicron subvariants and XBB recombinant variant 94%
- Clinical diagnosis of COVID-19: a prompt, feasible, and sensitive diagnostic tool for COVID-19 based on a 1,757-patient cohort (The AndroCoV Clinical Scoring for COVID-19 diagnosis) 93%
- Clearing the fog: Is Hydroxychloroquine effective in reducing Corona virus disease-2019 progression: A randomized controlled trial 93%
Similar papers in this journal
- Antibody response in individuals affected with Sars-Cov-2 infection: temporal trends and qualitative and quantitative differences in symptomatic and asymptomatic subjects. A Cross Sectional Analysis. Ab-Covid Study 95%
- Epidemiological And Clinical Characteristics Of COVID-19 Patients In Kenya 94%
- SARS-CoV-2 seroprevalence and living conditions in Bamako (Mali): a cross-sectional multistage household survey after the first epidemic wave, 2020 93%
Similar papers in this journal
- Evaluation of the disease outcome in Covid-19 infected patients by disease symptoms: a retrospective cross-sectional study in Ilam Province, Iran 94%
- Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel 94%
- Determinants of Developing Symptomatic Disease in Ethiopian COVID-19 Patients 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.